Nov 5, 6:47 AM ET
Cardinal Health reported first-quarter fiscal 2027 revenue of $67.5 billion, a 5% increase year-over-year, alongside a GAAP diluted EPS of $2.38. Driven by strong segment performance, the company raised its full-year non-GAAP diluted EPS guidance range to $12.80 to $13.00 and completed a $500 million share repurchase program.
- First-quarter revenue increased 5% to $67.5 billion compared to the prior-year period.
- GAAP diluted EPS grew 27% to $2.38 and non-GAAP diluted EPS grew 28% to $3.26.
- Fiscal year 2027 non-GAAP EPS guidance was raised to a range of $12.80 to $13.00.
- The company completed its $500 million share repurchase program during the first quarter.
Read the filing on SEC.gov ↗
Aug 11, 6:47 AM ET
Cardinal Health reported fourth-quarter and fiscal 2026 results on August 11, 2026, with revenue up 6% in the quarter and 14% for the year. Quarterly GAAP diluted EPS rose 70% to $1.70, including a one-time $0.31 benefit from IEEPA tariff refunds; excluding that benefit, non-GAAP EPS rose 25% to $2.60. The company guided fiscal 2027 non-GAAP EPS to $12.40 to $12.60, 13% to 15% growth, and the board approved a $5.0 billion increase to its share repurchase program.
- Fourth-quarter revenue rose 6% to $63.7 billion; GAAP operating earnings rose 70% to $729 million.
- Fiscal 2026 revenue was $254.2 billion, up 14%; GAAP diluted EPS was $7.23 and non-GAAP diluted EPS was $11.26.
- Fiscal 2027 guidance: non-GAAP diluted EPS of $12.40 to $12.60, with share repurchases of about $1 billion.
- Board approved a $5.0 billion repurchase increase, bringing total authorization to $6.4 billion; quarterly dividend of $0.5158 per share is payable October 15, 2026.
Read the filing on SEC.gov ↗
Aug 11, 6:38 AM ET
Cardinal Health signed a $4.0 billion unsecured revolving credit agreement running through August 7, 2031, and terminated its existing $2.0 billion five-year and $1.0 billion 364-day credit facilities plus a $1.0 billion receivables sale program. The new facility replaces those arrangements and is intended for general corporate purposes. The filing reports no termination penalties and a financial covenant requiring a Consolidated Net Leverage Ratio of no greater than 4.00 to 1.00.
- New $4.0 billion revolving credit facility matures August 7, 2031, with an option to extend by up to two years subject to conditions
- Terminated $2.0 billion five-year credit agreement dated February 27, 2023 and $1.0 billion 364-day credit agreement dated October 7, 2025
- Terminated $1.0 billion receivables sale program; the filing states no penalties were incurred
- Financial covenant requires Consolidated Net Leverage Ratio of no greater than 4.00 to 1.00 at each fiscal quarter end
Read the filing on SEC.gov ↗
Aug 5, 6:39 AM ET
Cardinal Health appointed Anita Zielinski, currently interim CFO and chief accounting officer at Baxter, as its Chief Accounting Officer effective November 5, 2026, succeeding Mary Scherer, who remains in the role until then. Ms. Zielinski joins Cardinal as Senior Vice President Finance on September 16, and her pay includes a $750,000 cash sign-on bonus and $1,000,000 in restricted share units to offset compensation forfeited at her former employer.
- Anita Zielinski appointed Chief Accounting Officer effective November 5, 2026; Mary Scherer serves through that date
- Zielinski joins Cardinal as Senior Vice President Finance effective September 16, 2026
- Sign-on package: $750,000 cash bonus and restricted share units with a $1,000,000 grant date value vesting over three years
- Zielinski previously served as interim CFO at Baxter International and spent seven years at Sysco Corporation
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.